Trial · NCT00525915
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
NCT00525915, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2015-02-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma. Trials, record NCT00525915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00525915
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
- NCT number
- NCT00525915
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 126 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Esophageal Cancer, Gastroesophageal Cancer
- Interventions
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy, Surgery
- First posted
- 2007-09-06
- Last updated
- 2015-02-09
- Results first posted
- 2015-02-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathologic Complete Response Rate | Surgery post chemotherapy (approximately 10-11 weeks) | Pathologic Complete Response rate: percentage of participants with response reported as Pathologic complete response (pathCR) following surgery. Once surgery performed, response to therapy judged in surgical specimen with three possible categories reported: 1) Pathologic complete response (no residual cancer in the specimen); 2) \<50% of residual cells in the surgical specimen; or 3) \>50% of cells in the surgical specimen. Upon recovery from chemoradiation (Chemo), surgery follows approximately 5-6 weeks later with response assessment. Arm A schedule consists of 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. Arm B schedule consist of 8 weeks of Chemo, followed by 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. In particular, Arm B is 8 weeks longer than Arm A. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pathologic Complete Response Rate | Surgery post chemotherapy (approximately 10-11 weeks) | Participants who had surgery were reported for the pathCR rate assessment in this outcome. | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pathologic Complete Response Rate | Arm A: Chemo With Radiation Treatment | 13 | percentage of participants | ||
| Pathologic Complete Response Rate | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 26 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Chemo With Radiation Treatment | 63 | |
| Overall Study | STARTED | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 63 | |
| Overall Study | COMPLETED | Arm A: Chemo With Radiation Treatment | 55 | |
| Overall Study | COMPLETED | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 54 | |
| Overall Study | NOT COMPLETED | Arm A: Chemo With Radiation Treatment | 8 | |
| Overall Study | NOT COMPLETED | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 9 |
Source ClinicalTrials.gov
Adverse events102
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANOREXIA | Gastrointestinal disorders | Arm A: Chemo With Radiation Treatment | 46 | 63 | 46 |
| other | ANOREXIA | Gastrointestinal disorders | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 43 | 63 | 43 |
| other | DERMATITIS (RADIATION) | Skin and subcutaneous tissue disorders | Arm A: Chemo With Radiation Treatment | 23 | 63 | 23 |
| other | DERMATITIS (RADIATION) | Skin and subcutaneous tissue disorders | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 16 | 63 | 16 |
| other | FATIGUE | General disorders | Arm A: Chemo With Radiation Treatment | 54 | 63 | 54 |
| other | FATIGUE | General disorders | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 51 | 63 | 51 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Arm A: Chemo With Radiation Treatment | 23 | 63 | 23 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 32 | 63 | 32 |
| other | GRANULOCYTOPENIA | Blood and lymphatic system disorders | Arm A: Chemo With Radiation Treatment | 4 | 63 | 4 |
| other | GRANULOCYTOPENIA | Blood and lymphatic system disorders | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 6 | 63 | 6 |
1 to 10 of 102Source ClinicalTrials.gov
See all 102 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: Chemo With Radiation Treatment | ||
| Total, all-cause mortality | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | ||
| Total, other adverse events | Arm A: Chemo With Radiation Treatment | 63 | 63 |
| Total, other adverse events | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 63 | 63 |
| Total, serious adverse events | Arm A: Chemo With Radiation Treatment | 10 | 63 |
| Total, serious adverse events | Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 7 | 63 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Arm A: Chemo With Radiation Treatment vs Arm B: Pre-Op Chemo + Chemo With Radiation Treatment: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00525915
GET https://conductscience.org/api/trials/v1/NCT00525915/events?page=2